Irving L. WeissmanRavindra MajetiArash Ash AlizadehMark P. ChaoUS20120282174 * Sep 15, 2010 Nov 8, 2012 Weissman Irving L Synergistic Anti-CD47 Therapy for Hematologic Cancers
The therapy combines an experimental antibody developed by researchers at Stanford and a commercially available anti-cancer antibody called rituximab. Theexperimental antibody, known as Hu5F9-G4, blocks the protein CD47, a "don't eat me" signal that inhibits immune attacks on cancer cells. The a...
(R/M HNSCC). The AK117-302 study represents a significant milestone as the first Phase III clinical trial globally to investigate a CD47 monoclonal antibody therapy for solid tumors. This trial is the fifth Phase III study for ivonescimab, utilizing PD-1/L1 monoclonal antibody therapy as a ...
CD47 therapy induces a dramatic enhancement in the intratumoral CD4+T cells. Changes in Tregs Intratumoral Tregs express CD4 and FoxP3 in both human and mouse and play a suppressive role in anti-tumor immunity [29]. Single-cell RNA-seq revealed two Treg clusters (Treg_s1 and Treg_s2) (Fig...
Combination Therapy with Anti-CD47 Antibody and Rituximab Eliminates Lymphoma in Both Disseminated and Localized Human NHL Xenotransplant Models In the second treatment strategy, mice were first engrafted with NHL and then administered single or combination antibody therapy. To best model NHL, we establi...
“With encouraging evidence of AO-176’s safety and anti-tumor activity as a single agent, we are expanding this trial to further evaluate this therapy in combination with chemotherapy in patients with select solid tumors,” said Julie Hambleton, M.D., Interim President and Chief Executive Offic...
antigen arm thereby potentially improving tumor cell selectivity and tolerability. A CD47 × CD20 antibody, which demonstrated tumor-selective binding, served as proof of concept for this approach. Interestingly, a combination effect was achieved through targeted antibody therapy and lowering the threshold...
4,5 Anti-CD47 therapy has been recently proposed to block the “do not eat” signal expressed on the surface of the cancer cells and atherosclerotic plaques to allow macrophages and neutrophils to clear them and subsequently destroy the tumor or the plaque.4,6 However, the systemic ...
Among these strategies related to macrophages targeted cancer immunotherapy [6], immune checkpoint inhibitor therapy, such as anti-CD47(aCD47), and the activation of M1 macrophages have shown notable success. The former therapeutic strategy utilizes aCD47 to disrupt the interaction between the overexpre...
E. Improving the efficacy of osteosarcoma therapy: combining drugs that turn cancer cell ‘don’t eat me’ signals off and ‘eat me’ signals on. Mol. Oncol. 13, 2049–2061 (2019). Article CAS PubMed PubMed Central Google Scholar Barkal, A. A. et al. CD24 signalling through ...